What Does Centene Do?
Founded in 1984 and headquartered in Saint Louis, Missouri, Centene is a leading managed care organisation serving government-sponsored healthcare programs. It operates across four segments: Medicaid (its historical core), Medicare, Commercial/Marketplace (ACA exchange plans), and Other (pharmacy, dental, vision, behavioural health). Serving roughly 1 in 15 Americans, Centene is the largest ACA Marketplace insurer in the US, with 5.6 million Marketplace enrollees — approximately 23% of total national ACA enrollment.
The Core Problem in One Number
Q2 2025 Health Benefits Ratio (HBR): 93.0% vs 87.6% prior year. For every $100 in premiums collected, $93 went to paying medical claims — before any administrative costs. This is not a sustainable operating model and is the root cause of the stock's collapse.
BQ Score — Business Quality
The Collapse — What Happened
In July 2025, Centene shares plunged ~40% in a single session after the company withdrew its full-year earnings outlook. Adjusted EPS guidance fell from approximately $7.25 to just $1.25–$1.75. The cause: a sicker-than-expected ACA Marketplace member pool, driven by the scheduled expiration of enhanced Advance Premium Tax Credits (APTCs) which brought in healthier, lower-income enrollees. As subsidies shrink, healthier people leave — and the remaining pool gets sicker.
| Period | Rev Growth | Op Margin | HBR | Net Income |
|---|
| FY 2024 | +4% | 2% | — | 3% |
| Q1 2025 | +15% | 3.2% | — | Positive |
| Q2 2025 | +22% | -1% | 93.0% | Negative |
| Q3 2025 | +18% | -14% | High | Negative |
Risk 1 — ACA Subsidy Dependency
Centene's Marketplace segment is the most subsidy-dependent book of business in US managed care. With 5.6M enrollees (23% of ACA market), any reduction or expiration of enhanced APTCs directly worsens the risk pool, increases medical costs, and squeezes margins. This is a political risk, not just a business risk.
Risk 2 — $6.7B Goodwill Impairment
In Q3 2025, Centene recorded a $6.7 billion goodwill impairment, attributed in part to the "non-renewal of Marketplace enhanced APTCs." This is a non-cash charge but signals that management has materially written down the value of the Marketplace business they once paid a premium to acquire.
The Policy Wildcard — Potential Upside
A Trump-backed ACA subsidy extension push in late 2025 triggered a ~8% single-day jump in CNC shares. If enhanced APTCs are extended, the risk pool improves, medical costs normalise, and Centene's margins could recover faster than the base case implies. Policy moves are the biggest near-term catalyst — in both directions.
Analyst View
20 analysts cover CNC — 5 Buy, 15 Hold/Sell. Targets range from $32 to $70, averaging $43.06 against a current price of $46.61. Projected revenue growth of 18.28% in 2025 but near-zero 0.15% in 2026 as the Marketplace drag weighs on the top line. Current P/E is negative (EPS: -$10.67). Forward P/E of 15.78× assumes a meaningful earnings recovery by 2026, which requires the margin situation to stabilise.
Easy Equity Verdict
High-policy-risk, high-morbidity — multiple things need to go right.
Centene's problems are structural, not cyclical. The Marketplace business is fundamentally exposed to government subsidy decisions, and the company has already taken a $6.7B goodwill write-down acknowledging the damage. The stock has bounced from its lows on policy hope — but a full recovery requires stable policy outcomes, disciplined repricing, and medical cost normalisation all happening simultaneously. We do not see enough margin of safety at current levels to justify entry. Track policy developments, and wait for at least two consecutive quarters of HBR improvement below 90% before reconsidering.